Key facts
- This page summarizes Eric Adler's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Feb 2025, 17:09.
Eric Adler - 19 Feb 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- LXEO
- Reported as of
- 19 Feb 2025
- Net transaction value
- -$10,410
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2025, 17:09:13 UTC
- Prior SEC filing
- 10 Jan 2025
- Next SEC filing
- 20 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Youjin Choi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Adler filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 21 Feb 2025.
Change
- Previous filing in this sequence was filed on 10 Jan 2025.
- Current net transaction value: -$10,410.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXEO
transaction
Common Stock
Sale
- Transaction value
- $10,410
- Shares
- -2,359
- Change %
- -3.3%
- Price
- $4.41
- Shares after
- 68,266
- Date
- 19 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
Footnote F2
Includes 63,906 RSUs.